Dublin, Aug. 16, 2017 -- The "Antibody Target, Technology & Pipeline Database: 1-Year Subscription" newsletter has been added to Research and Markets' offering.
Subscription to this proprietary Antibody Database provides online access to information about more than 3,400 project entries for therapeutic antibodies on the market and in research & development.
Pre-established and free search functions allow to identify antibodies according to their:
- Technology (e.g. bispecifics, T-cell redirecting antibodies, antibody-drug conjugate, Fc-engineering, antibody format)
- Target (e.g. VEGF, immuen checkpoint modulators)
- Pipelines (selected by target, therapeutic area, company, technology)
- Sales (for marketed antibodies)
- R&D Phase (clinical phases, market, preclinical)
- Territory (countrywise)
- Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
- Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed.
Sales figures of major therapeutic antibodies on the market are provided. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
- T-cell Redirecting Antibodies
- Immune Checkpoint Modulating Antibodies
- Antibody-Drug Conjugates
- Bispecific Antibodies
- Oligo- and Polyclonal Antibodies
- Biosimilar Antibodies
Benefits from the Antibody Pipeline Database:
- Intuitive use
- Continuously updated (input from e.g. press releases, scientific meetings, company presentations)
- Designed for structured searches
- Focused on targets, technologies, therapeutic areas and R&D phases
- Ideal for competitor analysis (companies, targets, technologies, R&D phase)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
Project listing in a tabular format:
- Drug Codes
- Target
- Class of Compound
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
Therapeutic Areas:
- Cardiovascular & blood
- Dermatology
- Gastrointestinal
- Genitourinary, renal & gynecology
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmology & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
Predefined Technologies of the Scroll-Down Menu - examples:
- T-Cell Redirecting Antibodies
- Antibody-Drug Conjugates per Payload (e.g. Auristatin, PBD)
- Bispecific Antibodies
- Oligo- and Polyclonal Antibodies
- In vitro generated Antibodies (phage display)
- Fab Antibodies
- Fc-Fusion Proteins
- Agonist Antibodies
- Transgenic Mouse Antibodies (e.g. XenoMouse, VelocImmune Mouse, KM Mouse)
- Human Cell-Derived Antibodies
Predefined Targets of the Scroll Down Menu - examples:
- Amyloid & Tau
- Antibody Sales in 2015
- Biosimilar Antibodies
- BCMA
- CD19
- CD20
- CD22
- CD30
- CD33
- CD37
- CD38
- CD40/-L
- CD123
- CEA
- CGRP
- EGF-R
- EpCAM
- FGF/-R
- GM-CSF
- Her2
- Interleukin-1/R
- Interleukin-6/R
- Interleukin-23 & 12/23
- Interleukin-4/-13
- Interleukin-17
- LAG-3
- Mesothelin
- OX40/-L
- PCSK9
- PSMA
- TIM-3
- TNF
For more information about this newsletter visit https://www.researchandmarkets.com/research/w3c2hq/antibody_target
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology


Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Robinhood Expands Sports Event Contracts With Player Performance Wagers
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 



